Affiliate disclosure: As an Amazon Associate, AgmatineHub earns from qualifying purchases. This helps support our research and content creation, and it does not affect what we recommend. Full disclosure.
Beta-alanine and agmatine occupy the same slot in a pre-workout label and almost nothing else in common. Beta-alanine is the reason your face tingles. Agmatine is the reason the label can say something about nitric oxide.
The interesting part of this comparison is not which is stronger. It is that beta-alanine shows you what a modest, honestly-reported supplement effect actually looks like once enough trials accumulate, and that gives you a yardstick for judging compounds like agmatine that have not been tested yet.
Key Takeaways
- Beta-alanine works by raising muscle carnosine, which buffers hydrogen ions during high-intensity work. Agmatine works at receptors (NMDA, imidazoline, alpha-2) and on nitric oxide synthase [1]. Different problems entirely.
- The largest beta-alanine meta-analysis pooled 40 studies, 65 exercise protocols and 1,461 participants and found a significant overall effect size of just 0.18 [2]. Small, but real, and honestly reported.
- That effect is conditional. Exercise duration significantly moderated it, with the benefit concentrated in efforts lasting roughly 0.5 to 10 minutes [2].
- A 2026 multilevel meta-analysis of 17 randomised controlled trials found no ergogenic effect of beta-alanine on repeated sprint ability at all: mean performance SMD was -0.018 (p = 0.841) [3]. Dose and duration did not rescue it.
- Agmatine has no equivalent number to report. There are no human trials of agmatine and exercise performance, so there is no effect size, no confidence interval, and no moderator analysis.
- The tingle from beta-alanine (paraesthesia) is a harmless nerve effect, not a sign the dose is working. Agmatine has no comparable sensory marker.
What Beta-Alanine Actually Does
Beta-alanine is the rate-limiting building block for carnosine, a dipeptide stored in skeletal muscle. Carnosine buffers the hydrogen ions that accumulate during high-intensity exercise and contribute to the burning sensation and eventual failure in efforts of a few minutes. Supplement beta-alanine for several weeks and muscle carnosine rises, which theoretically extends the time you can hold a high work rate.
That mechanism is well characterised, which is why beta-alanine has been tested so heavily. And the results are a useful lesson in calibration.
The Number Most People Never See
A systematic review and meta-analysis in the British Journal of Sports Medicine pulled together 40 individual studies using 65 different exercise protocols, producing 70 exercise measures across 1,461 participants. The pooled effect size was 0.18 (95 percent CI 0.08 to 0.28) [2]. That is statistically significant and practically small.
More useful than the headline number is the moderator analysis. Exercise duration significantly moderated the effect (p = 0.004), and within efforts of 0.5 to 10 minutes the type of exercise mattered too: exercise capacity measures showed an effect size of about 0.50, while performance measures showed about 0.11 and the confidence interval crossed zero [2]. Training status did not moderate anything.
Translated: beta-alanine helps a specific kind of effort, in a specific duration window, by a modest amount. It is not a general performance enhancer.
And Then the 2026 Null Result
A 2026 multilevel random-effects meta-analysis went after one specific claim: repeated sprint ability. It included 17 randomised controlled trials of at least two weeks of oral beta-alanine against placebo in healthy populations, assessed risk of bias with Cochrane RoB 2.0 and certainty with GRADE [3].
The results were null across the board. Mean repeated-sprint performance came out at SMD -0.018 (95 percent CI -0.207 to 0.170, p = 0.841). Peak performance was 0.205 (p = 0.130). Fatigue decrement was -0.020 (p = 0.929). Subgroup and meta-regression analyses confirmed that total dose, duration, exercise modality and training status did not moderate the null finding [3].
The authors gave a mechanistic explanation worth keeping: repeated sprinting is governed by very brief work bouts and phosphocreatine kinetics, so extra intracellular buffering capacity may simply be aimed at the wrong bottleneck.
Where Agmatine Sits
Agmatine cannot be compared on any of these axes, because the trials do not exist. Searching the human literature for agmatine and exercise performance returns nothing. There is no pooled effect size, no duration-window analysis, no null result to weigh against a positive one.
What exists is mechanism and pharmacokinetics. Agmatine acts on imidazoline I1 and I2 receptors, alpha-2 adrenoceptors, NMDA receptors and serotonergic receptors, and modulates nitric oxide synthase isoforms [1]. In rats, oral bioavailability is 29 to 35 percent with a plasma half-life of 74 to 117 minutes after oral dosing [4]. None of that tells you whether a set of squats goes better.
This is not an argument that agmatine does nothing. It is an argument that the honest label for it is “untested for this purpose,” which is a different thing from “weaker than beta-alanine” and also a different thing from “as good as.”
Practical Notes
The tingle
Beta-alanine causes paraesthesia, a harmless pins-and-needles sensation, usually in the face, neck and hands, from an effect on sensory nerve endings. It is dose-dependent and fades with sustained use or with split dosing. It is not a marker of efficacy, and buyers who treat it as one are calibrating on the wrong signal. Agmatine produces no comparable sensation, which some people misread as it being inert.
Loading time
Beta-alanine requires weeks of consistent dosing to raise muscle carnosine, which is why the meta-analysis restricted itself to chronic protocols and excluded crossover designs due to the long washout period [2]. It does nothing acutely, so its presence in a single-serving pre-workout is largely about the tingle. Agmatine, by contrast, has short pharmacokinetics and no loading rationale.
Stacking
No study has tested the two together. There is no mechanistic reason to expect interference, since they act on unrelated systems, but “no reason to expect a problem” is not evidence of benefit.
A Note on the Evidence
Agmatine sulfate is not FDA-approved to diagnose, treat, cure, or prevent any disease. This article is informational only and does not constitute medical advice.
Frequently Asked Questions
Is beta-alanine better than agmatine?
For high-intensity exercise lasting roughly half a minute to ten minutes, beta-alanine has a small but meta-analytically confirmed effect (pooled ES 0.18 across 1,461 participants). Agmatine has no human performance trials at all, so there is nothing to compare it against. That makes beta-alanine the evidenced choice for that specific use, not necessarily the better molecule overall.
Does agmatine cause the tingling that beta-alanine does?
No. The tingling, properly called paraesthesia, is specific to beta-alanine and comes from an effect on sensory nerve endings. It is harmless and fades with continued use or split dosing. Agmatine produces no equivalent sensation, which is not evidence either way about whether it is working.
Should I take both in the same pre-workout?
No study has tested the combination, and they act on unrelated systems, so there is no mechanistic reason to expect interference. Bear in mind beta-alanine only works after weeks of consistent daily dosing, so its presence in an occasional pre-workout serving contributes the tingle without the carnosine loading that produces the benefit.
Why did a 2026 study find beta-alanine does not work?
That meta-analysis looked specifically at repeated sprint ability across 17 randomised trials and found no effect on mean performance, peak performance, or fatigue decrement. This does not contradict the earlier positive findings: repeated sprinting depends on phosphocreatine kinetics over very brief bouts, which is not the bottleneck that extra carnosine buffering addresses.
References
- Kaur A, Kaur R, et al. Pharmacological profile of agmatine: An in-depth overview. Neuropeptides (2024). PMID 38608401
- Saunders B, et al. Beta-alanine supplementation to improve exercise capacity and performance: a systematic review and meta-analysis. Br J Sports Med (2017). PMID 27797728
- No ergogenic effect of beta-alanine on repeated sprint ability: a systematic review and multilevel meta-analysis of randomized controlled trials. Front Nutr (2026). PMID 41971372
- Clements JD, et al. Biodistribution of Agmatine to Brain and Spinal Cord after Systemic Delivery. J Pharmacol Exp Ther (2023). PMID 37770201
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.
